AGIOS PHARMACEUTICALS, INC. Additional Paid in Capital, Common Stock
AGIOS PHARMACEUTICALS, INC. (AGIO) had Additional Paid in Capital, Common Stock of $2.59 billion as of 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:AdditionalPaidInCapitalCommonStock · last filed 2026-07-30
- 2026-06-30: Additional Paid in Capital, Common Stock $2.59B.
- 2026-03-31: Additional Paid in Capital, Common Stock $2.57B.
- 2025-12-31: Additional Paid in Capital, Common Stock $2.56B.
- 2025-09-30: Additional Paid in Capital, Common Stock $2.54B.
| Period end | Additional Paid in Capital, Common Stock |
|---|---|
| 2026-06-30 | $2.59B 10-Q · filed 2026-07-30 |
| 2026-03-31 | $2.57B 10-Q · filed 2026-04-29 |
| 2025-12-31 | $2.56B 10-Q · filed 2026-07-30 |
| 2025-09-30 | $2.54B 10-Q · filed 2025-10-30 |
| 2025-06-30 | $2.52B 10-Q · filed 2025-07-31 |
| 2025-03-31 | $2.51B 10-Q · filed 2025-05-01 |
| 2024-12-31 | $2.49B 10-K · filed 2026-02-12 |
| 2024-09-30 | $2.48B 10-Q · filed 2024-10-31 |
| 2024-06-30 | $2.46B 10-Q · filed 2024-08-01 |
| 2024-03-31 | $2.45B 10-Q · filed 2024-05-02 |
| 2023-12-31 | $2.44B 10-K · filed 2025-02-13 |
| 2023-09-30 | $2.42B 10-Q · filed 2023-11-02 |
| 2023-06-30 | $2.41B 10-Q · filed 2023-08-03 |
| 2023-03-31 | $2.40B 10-Q · filed 2023-05-04 |
| 2022-12-31 | $2.39B 10-K · filed 2024-02-15 |
| 2022-09-30 | $2.37B 10-Q · filed 2022-11-03 |
| 2022-06-30 | $2.36B 10-Q · filed 2022-08-04 |
| 2022-03-31 | $2.35B 10-Q · filed 2022-05-05 |
| 2021-12-31 | $2.33B 10-K · filed 2023-02-23 |
| 2021-09-30 | $2.32B 10-Q · filed 2021-11-03 |
| 2021-06-30 | $2.31B 10-Q · filed 2021-07-29 |
| 2021-03-31 | $2.27B 10-Q · filed 2021-04-29 |
| 2020-12-31 | $2.24B 10-K · filed 2022-02-24 |
| 2020-09-30 | $2.23B 10-Q · filed 2020-11-05 |
| 2020-06-30 | $2.20B 10-Q · filed 2020-07-30 |
| 2020-03-31 | $2.18B 10-Q · filed 2020-04-30 |
| 2019-12-31 | $2.16B 10-K · filed 2021-02-25 |
| 2019-09-30 | $1.86B 10-Q · filed 2019-10-31 |
| 2019-06-30 | $1.84B 10-Q · filed 2019-08-01 |
| 2019-03-31 | $1.82B 10-Q · filed 2019-05-02 |
| 2018-12-31 | $1.79B 10-K · filed 2020-02-19 |
| 2018-09-30 | $1.78B 10-Q · filed 2018-11-01 |
| 2018-06-30 | $1.74B 10-Q · filed 2018-08-02 |
| 2018-03-31 | $1.72B 10-Q · filed 2018-05-04 |
| 2017-12-31 | $1.17B 10-K · filed 2019-02-14 |
| 2017-09-30 | $1.16B 10-Q · filed 2017-11-01 |
| 2017-06-30 | $1.14B 10-Q · filed 2017-08-08 |
| 2017-03-31 | $857.11M 10-Q · filed 2017-05-04 |
| 2016-12-31 | $842.01M 10-K · filed 2018-02-14 |
| 2016-09-30 | $828.04M 10-Q · filed 2016-11-03 |
| 2016-06-30 | $652.57M 10-Q · filed 2016-08-08 |
| 2016-03-31 | $640.12M 10-Q · filed 2016-05-09 |
| 2015-12-31 | $630.08M 10-K · filed 2017-02-16 |
| 2015-09-30 | $619.45M 10-Q · filed 2015-11-06 |
| 2015-06-30 | $607.71M 10-Q · filed 2015-08-07 |
| 2015-03-31 | $598.49M 10-Q · filed 2015-05-11 |
| 2014-12-31 | $591.33M 10-K · filed 2016-02-26 |
| 2014-09-30 | $347.95M 10-Q · filed 2014-11-07 |
| 2014-06-30 | $344.49M 10-Q · filed 2014-08-07 |
| 2014-03-31 | $246.97M 10-Q · filed 2014-05-09 |
| 2013-12-31 | $244.88M 10-K · filed 2015-02-24 |
| 2013-09-30 | $243.60M 10-Q · filed 2013-11-07 |
| 2013-06-30 | $2.84M 10-Q · filed 2013-09-05 |
| 2012-12-31 | $2.01M 10-K · filed 2014-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |